论文部分内容阅读
本文报导19例无合并症的轻度原发性高血压(舒张压95～105毫米汞柱)患者用苄氟噻嗪(Bendrofluazide)10毫克,每天1次口服治疗。在治疗开始前、治疗1个月后、以及在一年随访期间每隔3个月同时测定血清钾和体内钾总量。每次访视时记录血压。未予饮食控制和补钾。治疗后1个月时,平均血清钾水平降低(从4.31毫当量/升降至3.79毫当量/升,P<0.01),体内钾总量亦降低(从100％降至95.4％,P<0.05)。此后平均值升高(前者从3.79毫当量/升升至4.11毫当量/升,后者从95.4％升至98.3％),到第12个月时,两者水平与治疗前无显著差异。在这
This article reports 19 patients with mild essential hypertension without comorbidity (diastolic blood pressure 95-105 mm Hg) were treated with 10 mg of Bendrofluazide orally once daily. Both serum potassium and total body potassium were measured simultaneously before treatment, one month after treatment, and every three months during one year follow-up. Record blood pressure on each visit. No diet control and potassium. At one month after treatment, the mean serum potassium level decreased (from 4.31 meq / l to 3.79 meq / l, P <0.01) and the total amount of potassium in the body decreased from 100% to 95.4% (P <0.05) . After that, the mean value increased from 3.79 mEq / liter to 4.11 mEa / liter, while the latter rose from 95.4% to 98.3%. By the 12th month, there was no significant difference between the two levels before treatment. At this